Jordyn Sava

Articles

Teclistamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-Directed Therapy

September 29th 2023

Treatment with teclistamab led to responses in patients with relapsed/refractory multiple myeloma, including those previously exposed to anti-BCMA therapies.

Furmonertinib Generates Activity and Tolerable Safety in EGFR Exon 20 Insertion+ NSCLC

September 10th 2023

The use of the oral, brain penetrant, furmonertinib, resulted in encouraging responses and a tolerable safety profile in patients with advanced non–small cell lung cancer harboring EGFR exon 20 insertion mutations, according to data from the phase 1b FAVOUR trial.

Quizartinib Improves OS Irrespective of Allo-HCT in CR1 and Pre-Allo MRD Status in FLT3-ITD+ AML

September 9th 2023

Quizartinib plus standard intensive induction and consolidation therapy resulted in improved overall survival compared with placebo in patients with newly diagnosed, FLT3-ITD–positive AML irrespective of allogeneic hematopoietic cell transplantation in first complete remission and pre-allo minimal residual disease status.

Data Suggest Interim PET2 Scans Can be Omitted for Frontline Brentuximab Vedotin Regimens in Hodgkin Lymphoma

September 9th 2023

The incorporation of brentuximab vedotin (Adcetris) into the frontline treatment of patients with Hodgkin lymphoma correlates with superior efficacy, irrespective of PET2 results, suggesting loss of predictive value with the scan.

BGB-3245 Displays Early Antitumor Activity in Advanced/Refractory Solid Tumors With MAPK Pathway Mutations

April 17th 2023

The RAF dimer inhibitor BGB-3245 generated early efficacy signals with a tolerable safety profile in patients with advanced or refractory solid tumors harboring MAPK pathway mutations.

Neoadjuvant Durvalumab/Tremelimumab Plus Chemo Meets PFS End Point in Advanced Ovarian Cancer

March 27th 2023

Neoadjuvant treatment with the combination of durvalumab plus tremelimumab and chemotherapy elicited a promising 12-month progression-free survival rate in patients with advanced-stage ovarian cancer.

Ruxolitinib Provides ORR Benefit vs BAT in Early Treatment of SR-aGVHD

February 17th 2023

Early treatment with ruxolitinib led to high response rates in patients with steroid refractory acute graft-vs-host-disease, although benefits with ruxolitinib vs best available therapy were observed regardless of the timing of ruxolitinib administration.

Haploidentical Donors/Posttransplant Cyclophosphamide Produces Outcomes Similar to Matched Unrelated Donor Transplantation in Myelofibrosis

February 16th 2023

Haploidentical donors and posttransplant cyclophosphamide is a comparable alternative to matched unrelated donors for patients with myelofibrosis receiving blood or marrow transplant without matched sibling donors, although matched sibling donors, when available, remain the preferred donor option.

Lenvatinib Following Progression on Immunotherapy Demonstrates Efficacy in Second-line HCC

January 20th 2023

Second-line lenvatinib may produce a survival benefit in patients with advanced hepatocellular carcinoma who have progressed on immunotherapy.

Orelabrutinib Plus R-CHOP Demonstrates Impressive ORR, PFS Rates in Non-GCB DLBCL

September 12th 2022

The combination of orelabrutinib and R-CHOP elicited a favorable overall response rate and progression-free response rate in patients with previously untreated non–germinal center B-cell–like diffuse large B-cell lymphoma (DLBCL) with extranodal disease.

Abemaciclib Plus Aromatase Inhibitor Generates Survival Benefit in HR+/HER2- Breast Cancer

September 9th 2022

The addition of abemaciclib to a nonsteroidal aromatase inhibitor elicited an improvement in overall survival vs a nonsteroidal aromatase inhibitor alone in patients with hormone receptor–positive, HER2-negative, early-stage breast cancer.

Lenalidomide Combo Plus ASCT Provides Significant PFS Benefit in Multiple Myeloma With High-Risk Cytogenetics

August 26th 2022

The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.

Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma

August 26th 2022

Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.

Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

August 7th 2022

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer

June 6th 2022

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer

June 6th 2022

Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.

Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer

June 5th 2022

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML

June 4th 2022

The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.

Positive Harm-Benefit Data Found in PSA Screening for Black Patients With Prostate Cancer

May 15th 2022

Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.

Up-Front Avelumab Maintenance Improves OS in Urothelial Carcinoma

May 14th 2022

Avelumab plus best supportive care produced a benefit in overall survival in patients with advanced urothelial carcinoma that had not progressed with first-line platinum-based chemotherapy.